Samotolisib

Samotolisib (LY3023414) potently and selectively inhibits class I PI3K isoforms, DNA-PK, and mTORC1/2 with IC50s of 6.07 nM, 77.6 nM, 38 nM, 23.8 nM, 4.24 nM and 165 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ, DNA-PK and mTOR, respectively. Samotolisib potently inhibits mTORC1/2 at low nanomolar concentrations[1][2].

Product Specifications

CAS Number

[1386874-06-1]

Product Name Alternative

LY3023414

UNSPSC

12352005

Hazard Statement

H315, H319, H320

Target

Autophagy; DNA-PK; mTOR; PI3K

Type

Reference compound

Related Pathways

Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/LY3023414.html

Purity

99.27

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(N1C[C@@H](OC)C)N(C)C2=C1C3=CC(C4=CC(C(C)(O)C)=CN=C4)=CC=C3N=C2

Molecular Formula

C23H26N4O3

Molecular Weight

406.48

Precautions

H315, H319, H320

References & Citations

[1]Wei L, et al. Genomic profiling is predictive of response to CDDP treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts. Oncotarget. 2016 Nov 22;7 (47) :76374-76389.|[2]Smith MC, et al. Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth. Mol Cancer Ther. 2016 Oct;15 (10) :2344-2356